The pharmacokinetic and pharmacodynamic effects of vaginal devices releasing levonorgestrel (L-NOG) at a constant rate (in vitro release: approximately 20 micrograms/day) were studied in a group of 20 normally menstruating women during a period of 90 days of continuous use. Peripheral blood samples were withdrawn two or three times (in the great majority of subjects, on Mondays, Wednesdays and Fridays) during a pretreatment (control) cycle, during 90 days of exposure and during the first week following the removal of the device, and the levels of L-NOG, estradiol and progesterone were analyzed by radioimmunoassay techniques. In 8 of these subjects, endometrial biopsies were also taken during days 23 to 25 of the control cycle, and then 6 and 10 weeks following the insertion of the devices. In addition, the initial absorption rate and removal half-life of L-NOG were assessed in 7 subjects using the devices for a period of 8 days only. Following insertion of the devices, the levels of L-NOG rose very rapidly, and reached the final "plateau" in some 30 minutes' time. This was followed by a limited period of "burst" with doubling the levels for a few hours, after which the levels remained stable and diminished very slowly in a linear fashion with an average decline of 23-26% during 90 days, corresponding to a daily decrease of 0.2 to 0.3 per cent. The removal half-life (first compartment) after 90 days of exposure in 19 subjects was 16.1 (13.7-18.6) hours. Sixty-nine treatment segments of 30 days were studied with frequent hormone assays; of these, 20 (or 29%) were anovulatory, 13 (19%) exhibited inadequate luteal function, and 32 (52%) had normal ovulatory-like cycles. All endometrial biopsies obtained during the pretreatment cycle were normal secretory; of the 16 biopsies obtained during treatment, 4 were suppressed, 2 proliferative, 6 secretory, and 4 could not be dated because of bleeding. An assessment of the bleeding profiles during exposure to L-NOG revealed almost a doubling of the number of days with bleeding and spotting (35% compared to 18% during the pretreatment cycle). However, significantly more frequent bleeding was found in the 20 anovulatory segments (37.3%) than in the 36 normal ovulatory-like ones (27.7%). It is concluded that differences in the frequency of bleeding and spotting with low-dose progestogens may reflect differences in the frequency of ovulation inhibition just as much as differences in the hormonal profiles of the compounds administered.

Download full-text PDF

Source
http://dx.doi.org/10.1016/0010-7824(82)90132-9DOI Listing

Publication Analysis

Top Keywords

pharmacokinetic pharmacodynamic
8
vaginal devices
8
devices releasing
8
releasing levonorgestrel
8
days
8
period days
8
control cycle
8
days exposure
8
levels l-nog
8
endometrial biopsies
8

Similar Publications

Evaluating the Immunogenicity Risk of Protein Therapeutics by Augmenting T Cell Epitope Prediction with Clinical Factors.

AAPS J

January 2025

Department of BioAnalytical Sciences, Genentech Inc, South San Francisco, California, USA.

Protein-based therapeutics may elicit undesired immune responses in a subset of patients, leading to the production of anti-drug antibodies (ADA). In some cases, ADAs have been reported to affect the pharmacokinetics, efficacy and/or safety of the drug. Accurate prediction of the ADA response can help drug developers identify the immunogenicity risk of the drug candidates, thereby allowing them to make the necessary modifications to mitigate the immunogenicity.

View Article and Find Full Text PDF

Background: ATOR-1017 (evunzekibart) is a human agonistic immunoglobulin G4 antibody targeting the costimulatory receptor 4-1BB (CD137). ATOR-1017 activates T cells and natural killer cells in the tumor environment, leading to immune-mediated tumor cell death.

Methods: In this first-in-human, multicenter, phase I study, ATOR-1017 was administered intravenously every 21 days as a monotherapy to patients with advanced, unresectable solid tumors having received multiple standard-of-care treatments.

View Article and Find Full Text PDF

Fluorescence lifetime imaging in drug delivery research.

Adv Drug Deliv Rev

January 2025

Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 117997, Moscow, Russia; School of Mathematical and Physical Sciences, Faculty of Science and Engineering, Macquarie University, Sydney, NSW 2109, Australia; Research Center for Translational Medicine, Sirius University of Science and Technology, 354340, Sochi, Russia; National Research Ogarev Mordovia State University, Saransk, Mordovia Republic 430005, Russia.

Once an exotic add-on to fluorescence microscopy for life science research, fluorescence lifetime imaging (FLIm) has become a powerful and increasingly utilised technique owing to its self-calibration nature, which affords superior quantification over conventional steady-state fluorescence imaging. This review focuses on the state-of-the-art implementation of FLIm related to the formulation, release, dosage, and mechanism of action of drugs aimed for innovative diagnostics and therapy. Quantitative measurements using FLIm have appeared instrumental for encapsulated drug delivery design, pharmacokinetics and pharmacodynamics, pathological investigations, early disease diagnosis, and evaluation of therapeutic efficacy.

View Article and Find Full Text PDF

Valsartan (VST) is an angiotensin II receptor antagonist with low oral bioavailability. The present study developed a solid self-nanoemulsifying drug delivery system (S-SNEDDS) to enhance the oral absorption and bioavailability of VST. VST-loaded liquid SNEDDS (VST@L-SNEDDS) was prepared by investigating the solubility of VST and constructing the pseudo-ternary phase diagrams.

View Article and Find Full Text PDF

Chamuangone, a compound extracted from the leaves of Garcinia cowa, exhibits various biological activities. Yet, its absorption, distribution, metabolism, excretion, and toxicity (ADMET) profile as well as anti-inflammatory effects in macrophages remain unexplored. In this study, we employed a computational tool to predict the ADMET profile of chamuangone and performed molecular docking simulations to assess its interactions with key proteins involved in inflammatory pathways.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!